Sugi Predict

Sugi Predict / Compounds / SCHEMBL482094

SCHEMBL482094

SCHEMBL482094

O=[N+]([O-])c1cnc(Br)cc1Br

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ AAK1 Q2M2I8 1/20 0.41
▸ ALDH1A1 P00352 5/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP19A1 P11511 1/20 0.39
▸ MAPT P10636 5/20 0.39
▸ CYP1A2 P05177 2/20 0.37
▸ CTSB P07858 1/20 0.37
▸ PKM P14618 1/20 0.37
▸ MAPK1 P28482 2/20 0.36
▸ CYP2D6 P10635 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29738282 1.00 AAK1 (0.41) AAK1ALDH1A1CYP3A4CYP19A1MAPT
Ammonia Solution, Strong SCHEMBL28172715 0.98 AAK1 (0.41) AAK1ALDH1A1CYP3A4CYP19A1MAPT
SCHEMBL31083410 0.83 ALDH1A1 (0.41) AAK1ALDH1A1CYP3A4CYP19A1MAPT
SCHEMBL3996551 0.83 ALDH1A1 (0.41) AAK1ALDH1A1CYP3A4CYP19A1MAPT
SCHEMBL619628 0.80 TSHR (0.46) ALDH1A1CYP3A4MAPTPKMMAPK1
SCHEMBL30808757 0.80 TSHR (0.46) ALDH1A1CYP3A4MAPTPKMMAPK1
SCHEMBL2107234 0.80 ALDH1A1 (0.49) ALDH1A1CYP3A4MAPTCYP1A2SMN1; SMN2
SCHEMBL30441422 0.80 TDP1 (0.46) AAK1ALDH1A1CYP3A4MAPTCYP1A2
SCHEMBL29709755 0.80 ALDH1A1 (0.49) ALDH1A1CYP3A4MAPTCYP1A2SMN1; SMN2
SCHEMBL858456 0.80 TDP1 (0.46) ALDH1A1CYP3A4MAPTCYP1A2CTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4713320-A2 BCAT2 INHIBITORS Agios Pharmaceuticals, Inc. (US) 2026-03-25 — — EP disclosed
US-20250270196-A1 GLP-1 Receptor Agonists and Uses Thereof PFIZER INC. (US) 2025-08-28 — — US disclosed
US-20250257052-A1 GLP-1 RECEPTOR AGONISTS AND USES THEREOF PFIZER INC. (US) 2025-08-14 — — US disclosed
EP-4594318-A1 AKT1 MODULATORS Alterome Therapeutics, Inc. (US) 2025-08-06 — — EP disclosed
US-12331041-B2 GLP-1 receptor agonists and uses thereof PFIZER INC. (US) 2025-06-17 — — US disclosed
EP-3321268-B1 BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF AGENCY SCIENCE TECH & RES (SG) 2025-06-04 — — EP disclosed
US-12319669-B2 GLP-1 receptor agonists and uses thereof PFIZER INC. (US) 2025-06-03 — — US disclosed
EP-4539840-A1 KINASE MODULATORS AND METHODS OF USE THEREOF Neuron23, Inc. (US) 2025-04-23 — — EP disclosed
US-20250092040-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. 2025-03-20 — — US disclosed
US-20240424111-A1 Degrader Compounds and Uses Thereof CALICO LIFE SCIENCES LLC (US) 2024-12-26 — — US disclosed
US-20080318947-A1 Inhibitors of Akt Activity HEERDING DIRK A 2008-12-25 — — US disclosed
US-20080234261-A1 Preparation of 1,6-Disubstituted Azabenzimidazoles as Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-09-25 — — US disclosed
US-20080234261-A1 Preparation of 1,6-Disubstituted Azabenzimidazoles as Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-09-25 — — US disclosed
US-20080234261-A1 Preparation of 1,6-Disubstituted Azabenzimidazoles as Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-09-25 — — US disclosed
WO-2008051493-A2 HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE AS PROTEIN KINASE INHIBITORS SIGNAL PHARMACEUTICALS, LLC (US) 2008-05-02 — — WO disclosed
EP-1874768-A2 INHIBITORS OF AKT ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2008-01-09 — — EP disclosed
WO-2006113837-A2 INHIBITORS OF AKT ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2006-10-26 — — WO disclosed
EP-1675552-A2 PREPERATION OF 1,6-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2006-07-05 — — EP disclosed
WO-2005037197-A2 PREPERATION OF 1,6-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2005-04-28 — — WO disclosed
WO-2005037197-A2 PREPERATION OF 1,6-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2005-04-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12331041-B2 GLP-1 receptor agonists and uses thereof GLP1R, GIPR, GCGR AAK1 885/4885ALDH1A1 907/4885CYP3A4 2074/4885
US-20250257052-A1 GLP-1 RECEPTOR AGONISTS AND USES THEREOF GLP1R, GIPR, GPR119 AAK1 889/4885ALDH1A1 747/4885CYP3A4 1693/4885
US-20240424111-A1 Degrader Compounds and Uses Thereof PTPN1, PTPN2, PTPN5 AAK1 775/4885ALDH1A1 2830/4885CYP3A4 1863/4885
US-12319669-B2 GLP-1 receptor agonists and uses thereof GLP1R, GIPR, GPR119 AAK1 889/4885ALDH1A1 747/4885CYP3A4 1693/4885
US-20080318947-A1 Inhibitors of Akt Activity PI4KB, PIK3CA, AKT2 AAK1 291/4885ALDH1A1 4166/4885CYP3A4 3855/4885
US-20250270196-A1 GLP-1 Receptor Agonists and Uses Thereof GLP1R, GIPR, GCGR AAK1 885/4885ALDH1A1 907/4885CYP3A4 2074/4885
US-20250092040-A1 AKT1 MODULATORS AKT1S1, AKT1, AKT2 AAK1 354/4885ALDH1A1 4692/4885CYP3A4 4570/4885
US-20080234261-A1 Preparation of 1,6-Disubstituted Azabenzimidazoles as Kinase Inhibitors TNK2, ROCK1, ARHGDIB AAK1 473/4885ALDH1A1 4395/4885CYP3A4 3962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.